See more : Lacto Japan Co., Ltd. (3139.T) Income Statement Analysis – Financial Results
Complete financial analysis of SIGA Technologies, Inc. (SIGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SIGA Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hyfusin Group Holdings Limited (8512.HK) Income Statement Analysis – Financial Results
- ALPHA Corporation (3434.T) Income Statement Analysis – Financial Results
- Fisker Inc. (FSR) Income Statement Analysis – Financial Results
- Public Joint Stock Company Rosneft Oil Company (ROSN.L) Income Statement Analysis – Financial Results
- MobiVentures, Inc. (MBLV) Income Statement Analysis – Financial Results
SIGA Technologies, Inc. (SIGA)
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.92M | 110.78M | 133.67M | 124.96M | 26.74M | 477.05M | 12.27M | 14.99M | 8.18M | 3.14M | 5.52M | 8.97M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 483.12K | 500.00K | 500.00K | 700.00K | 100.00K |
| Cost of Revenue | 17.83M | 32.96M | 26.54M | 25.74M | 15.09M | 108.29M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -945.40K | -400.00K | -200.00K | 0.00 | 0.00 |
| Gross Profit | 122.09M | 77.82M | 107.13M | 99.22M | 11.66M | 368.77M | -4.41M | -4.72M | -4.95M | -7.69M | -8.34M | -9.24M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 1.43M | 900.00K | 700.00K | 700.00K | 100.00K |
| Gross Profit Ratio | 87.26% | 70.25% | 80.14% | 79.40% | 43.59% | 77.30% | -35.95% | -31.51% | -60.60% | -244.93% | -151.06% | -103.02% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 295.69% | 180.00% | 140.00% | 100.00% | 100.00% |
| Research & Development | 16.43M | 24.11M | 9.94M | 10.94M | 13.30M | 13.02M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 18.37M | 22.66M | 17.42M | 11.61M | 9.94M | 9.15M | 8.30M | 4.17M | 2.94M | 1.77M | 1.73M | 2.61M | 1.70M | 2.90M | 900.00K | 700.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.88M | 12.30M | 13.71M | 24.99M | 200.99M | 1.42M | 1.88M | 25.74M | 1.15M | 734.17K | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.41M | -188.47M | 11.82M | 9.53M | 0.00 | 8.13M | 7.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.04M | 35.12M | 17.32M | 14.00M | 13.25M | 12.88M | 12.30M | 13.71M | 10.58M | 12.52M | 13.24M | 11.41M | 25.74M | 9.28M | 8.27M | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 800.00K |
| Other Expenses | 0.00 | -24.11M | 710.15K | 719.14K | 726.11K | 78.94M | 16.79K | -1.66M | 42.20K | 1.07K | 1.50K | 522.00 | 0.00 | 0.00 | 4.35B | 0.00 | 0.00 | 0.00 | 0.00 | 2.12M | 136.75K | 0.00 | 117.26K | 945.40K | 400.00K | 200.00K | 100.00K | 0.00 |
| Operating Expenses | 22.04M | 35.12M | 18.03M | 14.72M | 13.98M | 13.67M | 13.21M | 14.62M | 11.59M | 13.51M | 14.67M | 13.29M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 8.51M | 4.40M | 5.90M | 3.00M | 1.50M |
| Cost & Expenses | 56.30M | 68.08M | 44.58M | 40.46M | 29.06M | 121.95M | 29.89M | 34.33M | 24.72M | 24.34M | 28.52M | 31.51M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 7.57M | 4.00M | 5.70M | 3.00M | 1.50M |
| Interest Income | 4.16M | 0.00 | 101.17K | 2.48M | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.26K | 34.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.02M | 15.77M | 15.48M | 14.76M | 14.06M | 266.73K | 455.81K | 1.21M | 172.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.68K | 550.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 538.29K | 517.64K | 522.37K | 529.81K | 527.00K | 69.63K | 132.19K | 174.28K | 247.36K | 351.56K | 463.14K | 419.36K | 568.29K | 625.34K | 475.09K | 459.88K | 1.25M | 1.56M | 1.33M | 1.05M | 739.56K | 317.03K | 556.86K | 945.40K | 400.00K | 200.00K | 100.00K | 900.00K |
| EBITDA | 84.16M | 43.22M | 89.62M | 85.03M | 1.03M | 355.17M | -23.44M | -25.45M | -38.48M | -211.13M | -23.13M | -21.78M | -21.87M | -27.57M | -11.40M | -8.28M | -6.21M | -5.25M | -1.20M | -8.32M | -4.56M | -3.05M | -2.70M | -6.14M | -3.08M | -5.00M | -1.80M | -500.00K |
| EBITDA Ratio | 60.15% | 39.48% | 67.12% | 68.47% | 3.84% | 91.00% | -142.43% | -139.01% | -198.83% | -664.03% | -408.36% | -246.53% | -312.41% | 17.57% | -41.01% | -104.33% | -120.00% | -29.85% | -17.10% | -283.50% | -603.84% | -884.91% | -199.45% | -1,238.31% | -620.00% | -740.00% | -314.29% | -500.00% |
| Operating Income | 83.62M | 42.70M | 89.09M | 84.50M | 500.09K | 355.10M | -18.85M | -31.01M | -30.95M | -209.67M | -23.52M | -22.54M | -31.38M | -12.72M | -11.88M | -8.74M | -7.46M | -6.81M | -2.53M | -9.45M | -5.29M | -3.37M | -3.26M | -7.08M | -3.50M | -5.20M | -2.30M | -1.40M |
| Operating Income Ratio | 59.76% | 38.55% | 66.65% | 67.62% | 1.87% | 74.44% | -153.63% | -206.94% | -378.59% | -6,677.64% | -426.07% | -251.21% | -246.60% | -66.21% | -86.01% | -108.32% | -111.41% | -93.84% | -29.87% | -513.72% | -723.60% | -976.95% | -281.31% | -1,466.21% | -700.00% | -1,040.00% | -328.57% | -1,400.00% |
| Total Other Income/Expenses | 4.16M | 1.43M | 218.94K | -10.99M | -7.86M | 56.54M | -19.48M | -8.67M | -8.04M | -2.27M | -1.28M | 632.05K | 8.94M | -37.45M | -5.74M | 137.53K | 1.82M | -3.09M | 244.79K | 74.97K | -136.75K | 0.00 | -392.37K | -155.59K | 0.00 | -1.30M | 0.00 | -900.00K |
| Income Before Tax | 87.78M | 44.13M | 89.31M | 73.51M | -10.18M | 411.64M | -38.33M | -39.68M | -38.99M | -211.93M | -24.80M | -22.37M | -22.44M | -19.40M | -17.62B | -8.60M | -5.64M | -9.90M | -2.29M | -12.06M | -5.43M | 0.00 | -3.65M | -7.24M | 0.00 | -6.50M | 0.00 | -2.30M |
| Income Before Tax Ratio | 62.73% | 39.84% | 66.81% | 58.83% | -38.06% | 86.29% | -312.41% | -264.78% | -476.88% | -6,749.87% | -449.26% | -249.39% | -176.31% | -100.96% | -127,556.62% | -106.62% | -84.17% | -136.39% | -26.99% | -655.72% | -742.29% | 0.00% | -315.15% | -1,498.41% | 0.00% | -1,300.00% | 0.00% | -2,300.00% |
| Income Tax Expense | 19.71M | 10.23M | 19.86M | 17.17M | -2.94M | -10.17M | -2.09M | 13.88K | 461.98K | 53.53M | -7.62M | -7.84M | -36.03M | 15.47M | 5.74M | -137.53K | -1.82M | 3.09M | -244.79K | 493.36K | -18.26K | -34.06K | 467.79K | 706.06K | 100.00K | 1.40M | -100.00K | 0.00 |
| Net Income | 68.07M | 33.90M | 69.45M | 56.34M | -7.24M | 421.81M | -36.24M | -39.70M | -39.45M | -265.46M | -17.18M | -14.53M | 13.59M | -28.20M | -17.62M | -8.60M | -5.64M | -9.90M | -2.29M | -9.37M | -5.28M | -3.33M | -3.73M | -7.79M | -3.60M | -6.60M | -2.20M | -2.30M |
| Net Income Ratio | 48.65% | 30.61% | 51.96% | 45.09% | -27.08% | 88.42% | -295.34% | -264.87% | -482.53% | -8,454.68% | -311.22% | -161.95% | 106.82% | -146.73% | -127.56% | -106.62% | -84.17% | -136.39% | -26.99% | -509.65% | -721.11% | -967.06% | -321.66% | -1,612.35% | -720.00% | -1,320.00% | -314.29% | -2,300.00% |
| EPS | 0.95 | 0.46 | 0.92 | 0.71 | -0.09 | 5.28 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.57 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| EPS Diluted | 0.95 | 0.46 | 0.91 | 0.71 | -0.09 | 5.10 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.09 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| Weighted Avg Shares Out | 71.36M | 72.93M | 75.32M | 79.26M | 81.03M | 79.92M | 78.77M | 57.19M | 53.78M | 53.41M | 52.05M | 51.64M | 50.93M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.58M | 6.54M | 3.89M | 3.07M |
| Weighted Avg Shares Out (Dil) | 71.68M | 73.55M | 76.40M | 79.44M | 82.18M | 82.71M | 78.87M | 57.19M | 53.78M | 53.42M | 52.37M | 51.64M | 54.06M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.59M | 6.55M | 3.89M | 3.07M |
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher...
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under...
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead...
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen,...
SIGA Technologies, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SIGA
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
SIGA Technologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SIGA
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
SIGA Technologies, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SIGA
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
SIGA Technologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SIGA
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
Source: https://incomestatements.info
Category: Stock Reports